6160 — Beigene Share Price
Last trade - 00:00- HK$124.90bn
- HK$105.80bn
- CNY9.57bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.23 | ||
| Price to Tang. Book | 4.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.16% | ||
| Return on Equity | -23.44% | ||
| Operating Margin | -59.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,310.03 | 2,954 | 2,120.2 | 7,588.96 | 9,566.41 | 17,405.5 | 21,728.83 | 64.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Directors
- John Oyler CHM (53)
- Xiaobin Wu PRE (59)
- Xiaodong Wang CFD (57)
- Julia Wang CFO (50)
- Jane Huang OTH (48)
- Hing Ling Chau SEC
- Anthony Hooper NED (66)
- Timothy Chen NID (64)
- Han Dugan NID (65)
- Donald Glazer NID (76)
- Michael Goller NID (46)
- Ranjeev Krishana NID (47)
- Thomas Malley NID (52)
- Alessandro Riva NID (61)
- Corazon Sanders NID (64)
- Qingqing Yi NID (49)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- October 28th, 2010
- Public Since
- February 3rd, 2016
- No. of Employees
- 9,212
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,358,374,143
- Address
- 94 Solaris Avenue,, Camana Bay, GRAND CAYMAN, KY1-1108
- Web
- https://www.beigene.com/
- Phone
- +1 3459494123
- Auditors
- Ernst & Young LLP
Upcoming Events for 6160
Similar to 6160
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:03 UTC, shares in Beigene are trading at HK$91.95. This share price information is delayed by 15 minutes.
Shares in Beigene last closed at HK$91.95 and the price had moved by -38.9% over the past 365 days. In terms of relative price strength the Beigene share price has underperformed the FTSE Developed Asia Pacific Index by -38.85% over the past year.
The overall consensus recommendation for Beigene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Beigene does not currently pay a dividend.
Beigene does not currently pay a dividend.
Beigene does not currently pay a dividend.
To buy shares in Beigene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$91.95, shares in Beigene had a market capitalisation of HK$124.90bn.
Here are the trading details for Beigene:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6160
Based on an overall assessment of its quality, value and momentum Beigene is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Beigene is HK$171.19. That is 86.18% above the last closing price of HK$91.95.
Analysts covering Beigene currently have a consensus Earnings Per Share (EPS) forecast of -CNY4.98 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beigene. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.32%.
As of the last closing price of HK$91.95, shares in Beigene were trading -13.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beigene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$91.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Beigene's management team is headed by:
- John Oyler - CHM
- Xiaobin Wu - PRE
- Xiaodong Wang - CFD
- Julia Wang - CFO
- Jane Huang - OTH
- Hing Ling Chau - SEC
- Anthony Hooper - NED
- Timothy Chen - NID
- Han Dugan - NID
- Donald Glazer - NID
- Michael Goller - NID
- Ranjeev Krishana - NID
- Thomas Malley - NID
- Alessandro Riva - NID
- Corazon Sanders - NID
- Qingqing Yi - NID